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A cDNA encoding the most presynaptically neurotoxic phospholipase A2, ammodytoxin A, from the venom of the long-nosed viper (Vipera 
ammodytes ammodytes) has been expressed in Escherichia eoli. Ammodytoxin A was produced as a fusion protein with the 81 N-terminal residues 
of adenylate kinase followed by the tetrapeptide r cognition site for factor Xa (IEGR) just preceding the first amino acid residue of the toxin. The 
fusion protein was expressed under the control of tac promoter without IPTG induction in the form of insoluble inclusion bodies. It was dissolved 
in guanidine hydrochloride, S-sulfonated and refolded in a reoxidation mixture including a reduced/oxidized glutathione redox couple. Ammo- 
dytoxin A was fully activated by limited hydrolysis with trypsin that preferentially cleaves the fusion protein at the factor Xa recognition site and 
purified by cation-exchange chromatography. The correct N-terminus was confirmed by protein sequencing. Recombinant ammodytoxin A has 
been proved to be indistinguishable from the native toxin in its enzymatic activity and toxicity. 
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1. INTRODUCTION 
Phospholipases A 2 (PLA2s) are a diverse family of 
mostly calcium-dependent lipolytic enzymes that cata- 
lyze the hydrolysis of the 2-acyl ester bond of 1,2-diacyl- 
3-sn-phosphoglycerides [1]. Snake PLAzs represent the 
top of evolutional diversity of 14 kDa class of PLA2s. 
Structurally similar snake PLAzs differ considerably in
their pharmacological activities including presynaptic 
and postsynaptic neurotoxicity, myotoxicity, cardiotox- 
icity, anticoagulant, convulsive, hypotensive, hemolytic, 
hemorrhagic and edema-inducing effects [2]. Presynap- 
tically neurotoxic snake PLA2s are very potent oxins 
that block release of acetylcholine atthe neuromuscular 
junction in a multi-step rocess [3]. Their mode of ac- 
tion at the molecular level is still not completely under- 
stood. During the first, presumably non-enzymatic step 
in this blockade, neurotoxin binds to a receptor in the 
presynaptic membrane, apparently one of potassium 
channels [4]. Experiments with different PLA2 neuro- 
toxins also indicate that probably several types of such 
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receptors exist [3]. In the following steps, which include 
PLA 2 enzymatic activity, toxin produces a complete 
neuromuscular blockade [5]. So far, it has not been 
possible to locate all the amino acid residues responsible 
for high toxicity of these PLA2s neither those responsi- 
ble for the initial binding to the receptor. This problem 
could be best approached by protein engineering which 
requires, however, expression of a fully active toxin to 
be achieved. Thus far this had eluded all attempts. 
Three single-chain presynaptically neurotoxic PLA 2 
isotoxins, ammodytoxins A, B and C, have been iso- 
lated from the venom of the long-nosed viper (Vipera 
ammodytes ammodytes) and their primary structures de- 
termined [6-8]. They show more than 97% identity in 
their amino acid sequences, but differ in toxicities by 
more than a factor of ten. Recently, all the three ammo- 
dytoxins have been cloned [9]. In this paper, we present 
the expression of the most neurotoxic, ammodytoxin A, 
as a fusion protein in E. coli, its refolding and final 
activation to produce recombinant toxin which is in its 
enzymatic and neurotoxic properties indistinguishable 
from the native neurotoxin. This is the first report of the 
expression of a presynaptically neurotoxic snake PLA 2. 
2. MATERIALS AND METHODS 
2.1. Materials 
Restriction and DNA modifying enzymes were purchased from 
Boehringer-Mannheim (Germany). Other chemicals of analytical 
grade were from Sigma (USA) or Serva (Germany) unless otherwise 
stated. Oligonucleotides were synthesized on an Applied Biosystems 
381A DNA synthesizer (USA) and purified by polyacrylamide gel 
electrophoresis. Trypsin from bovine pancreas (type III) was obtained 
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from Sigma. [c~-35S]dATP used for nucleotide sequencing was from 
Amersham (UK). The cDNA encoding ammodytoxin A used in this 
study was isolated from a V ammodytes ammodytes venom gland 
cDNA library as described previously [9]. The expression plasmid 
pMAX, a derivative of pKK223-3 and pUC 18 (both from Pharmacia, 
Sweden) encoding the N-terminal part of adenylate kinase of 81 amino 
acid residues under the control of tac promoter, was a generous gift 
of Prof. Tatsuya Samejima of Aoyama Gakuin University, Tokyo, 
Japan. The bacterial strain used for cloning E. coli DH5~ was from 
Gibco BRL (USA) and the one for expression E. coli JM109 from 
Promega (USA). 
2.2. Construction of the expression plasmid 
The original cDNA clone encoding ammodytoxin A in pUC9 con- 
tains two internal PstI sites, the first one in the middle of the coding 
region and the second just after the stop codon. Additionally, an 
EcoRI site is present at the codons encoding Glu-4 and Phe-5. The 
ammodytoxin A cDNA sequence was cleaved with EcoRIlPstI and 
inserted between the NcoI and Pstl sites of the expression plasmid 
pMAX using an NcoIlEcoRI synthetic assette. The cassette was con- 
structed from the oligonucleotides 5'-C-ATG-GTG-ATC-GAG- 
GGC-CGC-AGC-CTG-CTC-G-3'  and 5'-AA-TTC-GAG-CAG- 
GCT-GCG-GCC-CTC-GAT-CAC-3'. It encodes the recognition se- 
quence IEGR for cleavage with factor Xa just preceding the first 
amino acid residue, serine, in the sequence of mature ammodytoxin 
A. Finally, the missing PstI-PstI fragment coding for the second half 
of ammodytoxin A was ligated into the PstI site of the expression 
plasmid. Its correct orientation and the entire sequence of the con- 
struct were verified by nucleotide sequencing using V7Sequencing kit 
of Pharmacia. The final expression plasmid named pMAXA thus 
encodes ammodytoxin A as a fusion protein with the N-terminal 
sequence of adenylate kinase which can be cleaved off by factor Xa 
or trypsin. 
2.3. Expression of the fusion protein 
Routinely, a single fresh bacterial colony was picked from a M9 
plate supplemented with 50 ,ug/ml ampicillin, inoculated into 2.5 ml 
of M9 medium with ampicillin and grown overnight at 37°C. The 
overnight culture was used to inoculate 250 ml of LB medium contain- 
ing 100 ,ug/ml ampicillin in a 2 1 Erlemeyer flask. Bacterial culture was 
grown by shaking at 250 rpm and 37°C for 8 10 h to yield at the end 
about 2.2 g wet weight bacteria per liter of culture medium. If IPTG 
was used for induction, it was added at the final concentration of 0.4 
mM when the cell density had reached A600 = 0.6. Cells were harvested 
by centrifugation at 4000 x g for 10 min. Inclusion bodies were iso- 
lated according to the procedure of Marston et al. [10]. 
2.4. Refolding, activation and purification of the recombinant protein 
Inclusion body pellet recovered from 2 1 of bacterial culture was 
thoroughly washed with a solution containing 2 M urea, 1% Triton 
X-100 and 5 mM DTT, and sulfonated with NTSB in 6 M GdnHCI, 
0.3 M Na2SO3, pH 8.5 [11]. The fusion protein was precipitated by 1% 
acetic acid and dissolved in 100 ml of 6 M GdnHC1, 50 mM Tris-HC1, 
pH 8.0, 10 mM CaC12, 3 mM EDTA and 2 mM reduced glutathione. 
Refolding was performed by dilution 1:10 into a solution of 0.3 M 
GdnHCI, 50 mM Tris-HC1, pH 8.0, 10 mM CaCI2, 3 mM EDTA, 2 
mM reduced and 1 mM oxidized glutathione. After standing for about 
48 h at room temperature, the reoxidation mixture was concentrated 
to 100 ml by ultracentrifugation through a YM-10 membrane (Ami- 
con, USA) and trypsin was added to the final concentration of 4% by 
weight according to the fusion protein. Production of active ammo- 
dytoxin A was followed by measurement of PLA2 activity. After 2.5 
h of stirring at room temperature, the pH was adjusted to 5.0, super- 
natant concentrated by ultrafiltration and dialysed against 50 mM 
sodium acetate, pH 5.0, 1 mM EDTA. This solution was loaded onto 
a Mono-S HR 5/5 FPLC column (Pharmacia) and purified with a 
linear gradient o 50 mM sodium acetate, pH 5.0, 1 mM EDTA and 
2 M NaCI. Recombinant, more than 95% pure ammodytoxin A eluted 
as a sharp peak at about 0.6 M NaCI. The protein solution was 
desalted using a Centricon-10 microconcentrator (Amicon). 
2.5. SDS-PAGE 
Electrophoresis was performed on 8~5% gradient gels using the 
PhastSystem of Pharmacia. The gels were stained by Coomassie blue 
R 350 according to the instructions of the manufacturer (Pharmacia). 
2.6. Amino-terminal protein sequence analysis" 
Prior to sequencing, recombinant ammodytoxin A was desalted by 
HPLC (Milton Roy, USA) on a Chrompack reversed-phase C8 col- 
umn (100 mm x 3 mm) equilibrated with 0.1% TFA in water and 
eluted by a linear gradient of 80% acetonitrile containing 0.1% TFA 
(solution B). The flow rate was 1 ml/min. Absorbance was monitored 
at 215 nm. Fraction A was lyophilized and subjected to sequencing. 
For the N-terminal sequence determination of the recombinant pro- 
tein, an Applied Biosystems liquid-pulsed protein sequencer 475A, 
on-line connected to a phenylthiohydantoin-amino acid analyzer 
120A of the same manufacturer was used. 
2.7. Phospholipase A2 activity 
PLAz activity was measured titrimetrically on mixed micelles using 
a simple egg yolk assay [12]. The reaction mixture consisted of egg yolk 
phosphatidylcholine as a substrate in the presence of 1% Triton X-100 
and 10 mM CaC12. All the measurements were done at 40°C and pH 
8.0. One enzyme unit is defined as consumption of I mmol of NaOH 
per minute. Concentrations of ammodytoxin A were calculated from 
the absorbance at 280 nm using an A~o of 11.6 cm -t [13]. 
2.8. Toxicity testing 
Lethality of recombinant ammodytoxin A was determined by dis- 
solving different quantities of the toxin in 0.5 ml of 0.9% NaCI and 
intravenous injection to NMRI albino mice. The LDs0 was calculated 
using the method of Reed and Muench [14]. 
3. RESULTS 
The ammodytoxin A cDNA sequence was fused with 
a sequence coding for the first 81 amino acid residues 
of adenylate kinase by a linker encoding factor Xa rec- 
ognition site (shown in Fig. 1). As expected, expression 
of ammodytoxin A in E. coli led to formation of inclu- 
sion bodies in the cytoplasm. The fusion protein accu- 
mulated to a level of about 10% of the total bacterial 
protein (lane 3 in Fig. 2). We have also tested two other 
bacterial expression systems, a short-fusion protein ex- 
pression (MIEGR preceding the first amino acid resi- 
due of ammodytoxin) using the same tac promoter and 
periplasmic expression under the control of T7 pro- 
moter (data not shown). However, the expression levels 
were much lower. 
In order to obtain a good expression from the plas- 
mid pMAXA in E. coli JM109, it was crucial to start 
inoculation with a colony from a fresh transformation 
plate. Our attempts to express the fusion protein in a 10 
litre fermentor were not successful, as we found that the 
expression was relatively low in comparison to the one 
using shaking flasks. Additionally, it has been observed 
that in this system tac promoter is not tightly regulated. 
The recombinant protein could be produced to the same 
expression level with or without IPTG induction. Al- 
though expression of the fusion protein was not fatal for 
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Fig. 1. Schematic presentation f the expression plasmid pMAXA. 
Restriction enzyme sites: E, EcoRI; N, NcoI; P, PstI; H, HindlII. 
Other abbreviations u ed: Ptac, tac promoter; RBS, ribosome binding 
site; ColE1 ori, ColE1 origin of replication; Ap R, ~-lactamase g ne for 
ampicillin resistance. The N-terminal fusion part of adenylate kinase 
is indicated by a heavy shaded box, recognition site IEGR for factor 
Xa by a solid box and the coding sequence of ammodytoxin A by a 
light shaded box. The linker region is additionally presented enlarged. 
The amino acid residues of adenylate kinase are indicated by numbers 
in italics, residues of the IEGR site by Roman numerals and those of 
ammodytoxin A by upright numbers. Cleavage sites for NcoI, EcoRI 
and trypsin or factor Xa are denoted by arrows. 
Fig. 2. SDS-PAGE analysis of expression and purification of ammo- 
dytoxin A. Lanes 1 and 8, molecular weight standards (97.4, 66.2, 45, 
31, 21.5 and 14.4 kDa); lane 2, total protein from E. coli JM109 
without the expression plasmid; lane 3, total protein from the same 
strain with the expression plasmid pMAXA at the end of expression; 
lane 4, washed inclusion body pellet; lane 5, fusion protein after cleav- 
age with trypsin; lane 6, recombinant ammodytoxin A purified by 
FPLC; lane 7, native ammodytoxin A. Before loading, samples were 
boiled in loading buffer for 5 min in the presence of 0.2 M DTT. 
quence up to the 10th residue completely corresponded 
to the sequence of  native toxin. Specific enzymatic activ- 
ity of  recombinant  ammodytox in  A was about  300 U/ 
mg in the egg yolk assay and its intraperitoneal  LDs0 
about 0.02 mg/kg of  white mice. A lmost  the same values 
have been reported for ammodytox in  A isolated from 
the venom [15]. 
the host bacteria, about  50% retardat ion in growth was 
observed by measur ing the final cell density. 
After careful washing of  the inclusion body pellet, the 
recombinant  protein was more than 70% pure (see lane 
4 in Fig. 2). Before the final purif ication, the fusion 
protein was refolded and activated. The fusion protein 
was solubil ized in 6 M GdnHC1, S-sulfonated and re- 
folded at a concentrat ion of  about  50/zg/ml in a redox 
buffer including 0.9 M GdnHC1. After two days o f reox-  
idat ion and subsequent concentrat ion,  act ivation of  am- 
modytox in  A was performed with trypsin. In the first 
experiments, we used factor Xa for a specific cleavage. 
However, it was less efficient than trypsin, which was 
also able to degrade most of  the incorrectly folded fu- 
sion protein and is considerably cheaper. Using l imiting 
condit ions for tryptic activation, such as room tempera- 
ture, short time of  incubat ion and presence of  0.9 M 
GdnHC1, we were able to cleave about  70% of  the avail- 
able fusion protein (lane 5 in Fig. 2). The final purifica- 
t ion by FPLC on a cat ion-exchange r sin yielded about  
0.5 mg of  active ammodytox in  A per liter of  bacterial  
culture. Recombinant  ammodytox in  A appeared to be 
more than 95% pure (lane 6 in Fig. 2). Before appl ica- 
t ion to a protein sequencer, it was analysed by HPLC 
to show its homogeneity  (Fig. 3). The N-terminal  se- 
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Fig. 3. HPLC separation of recombinant ammodytoxin A (A) on a 
reversed-phase C8 column before N-terminal protein sequencing. For 
details ee section 2. 
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4. DISCUSSION 
Until now, PLA2s from various organisms have been 
produced in different expression systems including bac- 
terial [16-25], yeast [26-28] and mammalian hosts [29- 
34]. Expression of an active PLA2 possessing 5-7 disul- 
fide bonds in a reductive nvironment of the bacterial 
cytoplasm is practically impossible. The only possibility 
to express a correctly folded PLA 2 using a bacterial 
system is expression into the periplasmic space which 
has been reported for expression of the M8L mutant of 
notechis 11'2 PLA2 from the elapid snake Notechis 
scutatus cutatus [25]; the expression yield was, how- 
ever, low. In most cases, bacterial expression of PLAzs 
is accompanied by an in vitro refolding procedure. The 
early experiments on refolding of native PLA2s either 
from group I [35] or group II [36] showed almost a 
quantitative r covery of their structures and activities. 
These encouraging results have been followed by re- 
naturation of porcine pancreatic [16], bovine pancreatic 
[17,37], human non-pancreatic [19 21], snake non-neu- 
rotoxic [22,23] and bee venom PLA2s [24] expressed in 
E. coli. However, no expression of a snake neurotoxic 
PLA2, neither from family Elapidae (group I) nor from 
family Viperidae (group II), has been reported so far. 
One of the reasons might be that such a PLA 2 can only 
refold under the conditions which do not resemble those 
used for renaturation of acidic, non-neurotoxic snake 
PLA2s from Naja naja naja [22] and Agkistrodon pis- 
civorus piscivorus [23]. 
We expressed a potent presynaptically neurotoxic 
snake PLA 2 from V. ammodytes (Viperidae) in E. coli 
as a non-toxic fusion protein. The fusion protein can be 
renatured under the conditions imilar to the ones used 
for reoxidation of human non-pancreatic PLA2 [20]. 
Both PLA2s, ammodytoxin A and human non-pancre- 
atic PLA2, are very basic proteins that belong to group 
II PLAzs. Following reoxidation, recombinant ammo- 
dytoxin A is released from the fusion protein by limited 
trypsinolysis. The N-terminal fusion of adenylate kinase 
simulates the propeptide which is normally present in 
pancreatic type I PLA2s and prevents enzymatic activity 
and toxicity of the expressed fusion protein. The use of 
trypsin instead of factor Xa was feasible as properly 
folded recombinant ammodytoxin A was shown to be 
resistant against limited tryptic digestion. In a separate 
experiment, this finding was confirmed by incubation of 
native toxin with trypsin using the same conditions. 
Subsequent sequencing revealed no additional N-ter- 
mini that might result from trypsin treatment. Use of 
the enzymatic activation instead of frequently used 
chemical cleavage with cyanogen bromide does not re- 
quire any preliminary mutation of internal methionine 
residues and enables expression of the protein with a 
native sequence. Additionally, possible chemical modi- 
fications of the amino acid side groups are excluded. 
Tryptic degradation of incorrectly folded protein mole- 
cules also contributes to more efficient subsequent puri- 
fication of the correctly folded, active enzyme. 
The overall recovery of about 4% of pure recombi- 
nant ammodytoxin A with respect o the amount ex- 
pressed in a bacterial culture is somewhat lower than 
expected. There are at least two possible reasons for 
that. The most important one seems to be low efficiency 
of refolding including reoxidation of all 7 disulfide 
bonds which might be interfered by the presence of a 
single cysteine residue in the N-terminal part of adenyl- 
ate kinase. Exchange of this residue could result in a 
better ecovery, although it might be necessary to read- 
just the conditions for optimal refolding. The other 
major problem in refolding is extremely high affinity of 
this protein for surfaces. A considerable amount of re- 
combinant ammodytoxin A was lost due to its irrevers- 
ible non-specific binding during refolding where the 
concentration f the toxin has to be as low as 50/~g/ml. 
In conclusion, the amount of fully-active, recombi- 
nant ammodytoxin A we could get from the fusion pro- 
tein expressed in E. coli followed by its refolding, enzy- 
matic activation and easy purification has enabled us to 
start with production of the first mutants to approach 
the yet unknown molecular mechanism of its presynap- 
tic neurotoxicity by protein engineering. 
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